(RTTNews) - Amicus Therapeutics (FOLD) Wednesday reported net income of $14.7 million, or $0.05 per share for the fourth quarter, compared with net loss of $33.8 million, or $0.11 per share for the same quarter a year ago.
Excluding one-time items, earnings were $29.2 million or $0.09 per share compared with $2.6 million or $0.01 per share last year.
Product sales grew 30 percent to $149.71 million from $115.08 million in the previous year.
Analysts on average, expected the company to report earnings of $0.09 per share on revenue of $147.87 million. Analysts' estimates typically exclude special items.
For fiscal 2025, the company expects revenue growth in the range of 17 percent - 24 percent. The Street is looking for revenue growth of 20.68 percent. The company also sees positive net income in the second half of 2025.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
